By [Your Name/Journalist Name]
The final quarter of the calendar year is traditionally a period of reflection and celebration, but for the leadership and advocates at METAvivor, it marks the most critical juncture for the future of metastatic breast cancer (MBC) research. Following the conclusion of the San Antonio Breast Cancer Symposium (SABCS)—the world’s premier gathering for breast cancer professionals—METAvivor President Dr. Kelly Shanahan has outlined a comprehensive strategic roadmap for the coming year. This plan integrates record-breaking grant cycles, expanded patient support frameworks, and a fundamental shift in how patient advocates interface with the global scientific community.
As the only national organization that exclusively funds annual stage IV breast cancer research, METAvivor finds itself at a pivotal moment. The intersection of holiday fundraising and scientific evaluation determines the trajectory of life-extending research for the coming year.
Main Facts: A Dual Focus on Science and Support
At the heart of METAvivor’s mission is the conviction that metastatic breast cancer requires a dedicated, specialized research focus that differs from early-stage prevention. Dr. Shanahan’s recent year-end update highlights several core pillars that will define the organization’s 2024 agenda:
The R.I.S.E. Initiative
One of the most significant announcements is the launch of R.I.S.E. (Reach. Inform. Support. Empower). This program represents a strategic reinvention of the former "Sea to Sea for MBC" program. While the previous iteration focused on cross-country awareness, R.I.S.E. is designed to be more targeted and impactful. The initiative aims to utilize board members and volunteers to penetrate under-resourced populations. By focusing on health equity, METAvivor seeks to ensure that advancements in MBC treatment and support are accessible to all patients, regardless of socioeconomic status or geographic location.
Peer-to-Peer Expansion and Global Interest
METAvivor’s Peer-to-Peer support groups have long been a cornerstone of their patient-centric model. During the recent symposium in San Antonio, the program garnered international attention. Dr. Shanahan reported that oncologists from Morocco expressed a formal interest in adopting METAvivor’s peer-to-peer training modules for their developing advocacy groups. This potential expansion signals a shift for METAvivor from a domestic funding body to a global influencer in patient advocacy standards.
The 2023-2024 Grant Cycle
The scale of METAvivor’s research funding continues to grow. This year, the organization processed nearly 200 Letters of Intent (LOIs) from researchers worldwide. Following a rigorous vetting process by the Scientific Advisory Board, 65 investigators were invited to submit full applications. This culminated in 62 comprehensive proposals currently under review, spanning quality of life, translational research, and early-career grants.
Chronology: From Thanksgiving to the New Year
The timeline of METAvivor’s year-end activities reflects a high-intensity period where fundraising meets scientific scrutiny.
- Late November (Post-Thanksgiving): The METAvivor Board of Directors convened to review the formal recommendations provided by the Scientific Advisory Board. This meeting is the culmination of months of peer review, where the financial capacity of the organization is weighed against the scientific merit of the grant applications.
- Early December (SABCS Week): A significant delegation from the METAvivor board, including Dr. Shanahan, Executive Director Crystal Moore, and board members Janice Cowden, Amy Beumer, Nathaniel Robinson, and Sharon Anderson, attended the San Antonio Breast Cancer Symposium.
- During the Symposium: The leadership conducted 11 formal meetings with potential corporate and private sponsors. These discussions are vital for securing the "Stage IV Stampede" and the annual "Summit," which serve as primary advocacy platforms for the MBC community.
- Mid-December (Post-SABCS): The organization entered a follow-up phase, converting the informal networking sessions from San Antonio into formalized funding agreements. Dr. Shanahan also began the process of synthesizing data from the symposium’s recorded sessions to share with the broader MBC community.
- Early January (Upcoming): METAvivor is scheduled to officially announce the recipients of the 2023-2024 grant awards. This period will also see the distribution of a survey regarding the R.I.S.E. program to gauge volunteer interest and community needs.
Supporting Data: The Metrics of Research Funding
The health of METAvivor is inextricably linked to its ability to fund high-level science. The data from the current grant cycle provides a window into the current priorities of the oncology research community.
Of the 62 full applications received, the breakdown by category is as follows:
- Translational Research (36 Applications): This represents the largest segment, focusing on "bench-to-bedside" science. These projects aim to take laboratory discoveries and move them into clinical trials, a critical need for patients who have exhausted standard-of-care treatments.
- Early Career Grants (16 Applications): These grants are designed to keep young, brilliant minds in the field of metastatic research. By funding researchers at the start of their careers, METAvivor is building a sustainable pipeline of MBC specialists.
- Quality of Life (10 Applications): Recognizing that "living" with cancer is as important as "treating" it, these applications focus on symptom management, psychological support, and palliative care innovations.
- Advisor’s Award (1 Application): A specialized recognition for significant contributions to the field by a member of the Scientific Advisory Board.
The sheer volume of LOIs (nearly 200) suggests that the demand for MBC-specific funding is far outstripping current supply. Dr. Shanahan noted that the number of grants funded is "100% dependent" on the success of end-of-year fundraising, highlighting the direct link between donor contributions and scientific progress.
Official Responses: The Advocate as a Colleague
A significant theme of this year’s symposium was the evolving role of the patient advocate. For decades, advocates were often viewed as peripheral to the "hard science" of oncology. However, the 2023 symposium marked a definitive shift in this dynamic.
Dr. Dennis Slamon, a legendary figure in oncology and the developer of trastuzumab (Herceptin), provided a powerful endorsement of the advocate’s role during his plenary session. He stated that advocates are "not just fundraisers and cheerleaders for research," but rather "colleagues whose inclusion in the design of clinical trials makes the trials better and innovation faster."
Dr. Shanahan echoed this sentiment, noting the contributions of board members Janice Cowden and Amy Beumer, who served on expert panels during the symposium. "They brilliantly represented the voice of us—the experts in living with cancer," Shanahan remarked. This philosophy—that patients are the ultimate "experts" in the disease—is now being integrated into trial designs, ensuring that endpoints are meaningful to those actually receiving the treatments.
Furthermore, the interest from the Moroccan medical community underscores the universal need for METAvivor’s model. The peer-to-peer training program is no longer just a support tool; it is being viewed as a clinical necessity for improving patient outcomes globally.
Implications: The Future of MBC Advocacy and Research
The activities of METAvivor at the end of 2023 carry heavy implications for the metastatic breast cancer landscape in 2024 and beyond.
1. Shifting the Research Paradigm
By heavily favoring translational research (36 out of 62 applications), METAvivor is signaling a move toward more aggressive, results-oriented science. The goal is to reduce the time it takes for a new compound or strategy to reach the patient. As more researchers look to METAvivor for funding, the organization’s influence on the direction of MBC research grows, forcing a greater focus on the metastatic stage which is often neglected in broader "pink ribbon" campaigns.
2. Addressing Health Disparities
The R.I.S.E. program’s focus on under-resourced populations addresses a long-standing criticism of the oncology field: that the benefits of new research often only reach those in major urban centers or high-income brackets. If R.I.S.E. succeeds, METAvivor could provide a blueprint for how disease-specific nonprofits can bridge the gap in healthcare equity.
3. The Professionalization of Advocacy
The recognition by Dr. Slamon and the inclusion of METAvivor members on scientific panels suggest that the "patient voice" is becoming a professionalized component of drug development. This leads to trials with better recruitment rates and more relevant "quality of life" metrics, ultimately speeding up the FDA approval process for new therapies.
4. Global Scaling
The potential for peer-to-peer training in Morocco may be the first step in METAvivor becoming an international umbrella organization. As metastatic breast cancer rates rise globally, the METAvivor model of "patient-funded, patient-led" research offers a compelling alternative to government-funded models that may be slower to adapt to new scientific breakthroughs.
In conclusion, as Dr. Shanahan and her team prepare for the January grant announcements, the message remains clear: the fight against metastatic breast cancer is moving from the sidelines of the medical community to the center of the laboratory. Through a combination of rigorous science, international collaboration, and a renewed focus on equity, METAvivor is attempting to transform a terminal diagnosis into a manageable chronic condition. The success of these initiatives, however, remains tethered to the continued support of a donor base that recognizes the urgency of the Stage IV community.
About the Author
